ESPR: Esperion Therapeutics, Inc. Stock

by  •  • Comments Off on ESPR: Esperion Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 227.51
Enterprise Value ($M) 702.08
Book Value ($M) -388.72
Book Value / Share -1.98
Price / Book -0.59
NCAV ($M) -431.46
NCAV / Share -2.20
Price / NCAV -0.53

Profitability (mra)
Return on Invested Capital (ROIC) -0.75
Return on Assets (ROA) -0.41
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.81
Current Ratio 1.18

Balance Sheet (mrq) ($M)
Current Assets 318.78
Assets 324.03
Liabilities 750.24
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 332.31
Operating Income 54.40
Net Income -51.74
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -23.65
Cash from Investing -0.32
Cash from Financing 86.48

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-07 13G/A Wasatch Advisors Inc 5.50
03-10 13G/A Bb Biotech Ag 4.90 -2.51
11-14 13G/A Two Seas Capital LP 3.30 -14.34
11-12 13G/A Vanguard Group Inc 6.64 0.00
11-08 13G BlackRock, Inc. 7.30 0.00
10-17 13G/A Millennium Management Llc 1.70 -66.56

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-05 870,089 4,836,551 17.99
2025-06-04 965,818 5,344,251 18.07
2025-06-03 887,139 4,428,375 20.03
2025-06-02 2,129,030 5,698,340 37.36

(click for more detail)

Similar Companies
CURR – CURRENC Group Inc. CVAC – CureVac N.V.
EOLS – Evolus, Inc. ETNB – 89bio, Inc.
ETON – Eton Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io